Alnoor Ramji

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Marc Bourlière, Stuart C. Gordon, Steven L. Flamm et al. · New England Journal of Medicine · 2017 · 558 citations

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie Razavi, Imam Waked, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2014 · 484 citations · Full text

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Strategies to manage hepatitis<scp>C</scp>virus (<scp>HCV</scp>) disease burden

Heiner Wedemeyer, A.‐S. Duberg, Marı́a Buti et al. · Journal of Viral Hepatitis · 2014 · 181 citations · Full text